Product Description
The radioactive inert gas xenon (133Xe) is a well-established isotopic indicator used to assess vascular status in many organ systems. We employed xenon-133 to evaluate male impotence. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6691197/)
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Canada | Colombia | France | Germany | Ireland | Italy | Pakistan | Portugal | Russia | Sweden | Taiwan | Turkey | Ukraine | United States
Approved Indications: None
Known Adverse Events: None
Company: Air Liquide Santé International
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Aneurysm|Cerebral Hemorrhage|Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis|Subarachnoid Hemorrhage|Unconsciousness
Phase 1: Chronic Obstructive Pulmonary Disease|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05433961 | P1 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-06-30 |
53% |
| NCT05433961 | P1 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-06-30 |
53% |
| NCT05302817 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer |
2027-08-31 |
44% |
| NCT05302817 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer |
2027-08-31 |
44% |
| XENON ILD | P2 |
Recruiting |
Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis |
2026-06-01 |
|
| Xe-SAH | P2 |
Unknown status |
Unconsciousness|Aneurysm|Cerebral Hemorrhage|Subarachnoid Hemorrhage |
2025-06-09 |